BIBLIOGRAPHIE : Substances psychédéliques : anthropologie, sociologie, spiritualité, chamanisme, culture… Docteur Christian Sueur, GRECC, mai 2020 Substances psychédéliques, anthropologie, sociologie, culture… : pp 1 - 6 Substances psychédéliques et Chamanisme : pp 7 - 10 Psychédéliques et “spiritualité” : religion, mysticisme, enthéogènes : pp 11 - 23
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie, … Dr Christian SUEUR, GRECC, mai 2020 (nouvelle version) Substances psychédéliques : Généralités, Pharmacologie, Neurophysiologie : 1 - 17 Substances psychédéliques et «psychologie » : 18 - 20 Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, culture, chamanisme, spiritualité, religion… Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca, Bibliographie : Mescaline et Peyotl, Bibliographie : MDMA, Bibliographie : Tryptamines …
Lire la suiteBIBLIOGRAPHIE : LSD Docteur Christian Sueur, GRECC, mai 2020 (nouvelle version). 1 – LSD : Généralités : 1 - 4 2 – LSD : Effets psychologiques : 5 - 6 3 – LSD : Pharmacologie, Neurophysiologie : 7 – 12 4 – LSD et culture alternative : 13 5 – LSD et thérapies psychédéliques : 14 - 18
Lire la suitePharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects Friederike Holze, Urs Duthaler, Patrick Vizeli, Felix Müller, Stefan Borgwardt, Matthias E. Liechti British Journal of Clinical Pharmacology, March 2019 Doi : 10.1111/bcp.13918 Aims : The aim of the present study was to characterize the pharmacokinetics and exposure–subjective response relationship of a novel oral solution of lysergic acid diethylamide (LSD) that was developed for clinical use in research and patients. Method : LSD (100 μg) was administered in 27 healthy subjects using a placebocontrolled, double‐blind, cross‐over design. Plasma levels of LSD, nor‐LSD, and 2‐ oxo‐3‐hydroxy‐LSD (O‐H‐LSD) and subjective drug effects were assessed [...]
Lire la suiteDe la première vague à la renaissance psychédélique ATHS 2019, Biarritz, 1-4 octobre 2019 Dr Bertrand LEBEAU LEIBOVICI Les psychédéliques « classiques » A l’exception du LSD, ce sont des substances naturelles consommées par certains peuples depuis des millénaires Les psychédéliques « classiques » interagissent avec le récepteur 5HT2a : LSD psilocybine DMT (Diméthyltryptamine) mescaline Une définition plus large des psychédéliques : Les entactogènes et empathogènes: MDMA, MDA, 2-CB, 2C-T-7 etc. Les substances dissociatives antagonistes NMDA : kétamine, PCP Les substances dissociatives agonistes kappa-opioïdes : ibogaïne et Salvia Divinorum Tryptamines et phényléthylamines : Les psychédéliques sont : soit des tryptamines : LSD, psilocybine, DMT, ibogaïne, bufoténine (5-hydroxy-DMT) soit des phényléthylamines: MDMA, mescaline, MDA, 2C-B etc. La psychiatrie en [...]
Lire la suiteThe Consciousness Research of Stanislav Grof : A Cosmic Portal Beyond Individuality By Richard Yensen, Ph.D. and Donna A. Dryer, M.D., M.P.H. ©1998 Richard Yensen & Donna Dryer I. Introduction Stanislav Grof began his research in Prague, Czechoslovakia, as a psychiatric resident, in the late 1950’s. His initial observations seemed to confirm and offer a laboratory proof for many of the basic tenets of Freudian psychoanalytic thought. At that time his conclusion was politically unsettling because psychoanalysis was repressed in the iron curtain countries. Forty years later the outcome of Grof’s continued research is a theoretical framework for understanding human consciousness. His theory has [...]
Lire la suiteLSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814 Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]
Lire la suiteLong-term effects of psychedelic drugs : A systematic review Jacob S.Adaya, Cayla M.Mitzkovitz, Emily K.Bloesch, Christopher C.Davoli, Alan K.Davis Neuroscience and Biobehavioral Reviews, 2020. Doi : 10.1016/j.neubiorev.2020.03.017 A B S T R A C T Research into the basic effects and therapeutic applications of psychedelic drugs has grown considerably in recent years. Yet, pressing questions remain regarding the substances’ lasting effects. Although individual studies have begun monitoring sustained changes, no study to-date has synthesized this information. Therefore, this systematic review aims to fill this important gap in the literature by synthesizing results from 34 contemporary experimental studies which included classic psychedelics, human subjects, and follow-up [...]
Lire la suitePsychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]
Lire la suiteMicrodosing psychedelics : Motivations, subjective effects and harm reduction, Toby Lea et al., 2020
Microdosing psychedelics : Motivations, subjective effects and harm reduction Toby Lea, Nicole Amada, Henrik Jungaberl, Henrike Schecke, Michael Klein International Journal of Drug Policy, 2020, 75, 102600, 9 p. Doi : 10.1016/j.drugpo.2019.11.008 A B S T R A C T Background : In recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term benefits, unwanted effects, and harm reduction practices. Methods : An international online survey [...]
Lire la suite